Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Capmatinib for advanced, EGFR wild type, c-Met amplified, non-small cell lung cancer – second or third line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Capmatinib is a new drug to treat non-small cell lung cancer. Non-small cell lung cancer is the most common type of lung cancer. It is often diagnosed late and is difficult to treat once it has spread to other parts of the body. Capmatinib is taken as a tablet and may offer a new treatment option for people whose cancer has returned after their previous treatments. Indexing Status Subject indexing assigned by CRD MeSH Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Receptor, Epidermal Growth Factor Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016001025 Date abstract record published 11/10/2016 |